G1 TherapeuticsGTHX
Market Cap: 204M
About: G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Employees: 100
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
140% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $1.76M
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
60% more capital invested
Capital invested by funds: $38.5M [Q4 2023] → $61.6M (+$23.1M) [Q1 2024]
3.06% more ownership
Funds ownership: 24.34% [Q4 2023] → 27.41% (+3.06%) [Q1 2024]
0% more funds holding
Funds holding: 86 [Q4 2023] → 86 (+0) [Q1 2024]
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
Research analyst outlook
13 Wall Street Analysts provided 1 year price forecasts over the past 6 months
13 analyst ratings
HC Wainwright & Co. Edward White | 23%downside $3 | Buy Maintained | 25 Jun 2024 |
Needham Gil Blum | 53%upside $6 | Buy Maintained | 25 Jun 2024 |
Needham Gil Blum | 207%upside $12 | Buy Reiterated | 13 Jun 2024 |
HC Wainwright & Co. Edward White | 130%upside $9 | Buy Reiterated | 28 May 2024 |
Needham Gil Blum | 207%upside $12 | Buy Reiterated | 28 May 2024 |
Financial journalist opinion
Based on 4 articles about GTHX published over the past 30 days